Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eucalyptus camaldulensis extract is derived from the leaves of the Eucalyptus camaldulensis tree, also known as red gum. It contains a range of phytochemicals, including ellagitannins (e.g., tellimagrandin I, pedunculagin, castalagin/vescalagin), monoterpenes (notably p-cymene, aromadendrene, 1,8-cineole), and other triterpenoids. Traditionally, it has been used as a remedy for respiratory diseases (colds, coughs, asthma, sore throat), gastrointestinal symptoms (colic, diarrhea), wounds, and muscle pain. In vitro and in vivo studies indicate it has multiple biological activities: antimicrobial (including activity against methicillin-resistant Staphylococcus aureus, Staphylococcus aureus, Proteus vulgaris, Candida albicans, Escherichia coli, Listeria monocytogenes, Bacillus cereus), anti-inflammatory, antioxidant, anti-ulcer, antinociceptive, spasmolytic, and astringent effects. Its mechanism of action is believed to involve disruption of microbial membranes and inhibition of microbial growth, as well as possible modulation of oxidative stress and inflammation[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eucalyptus camaldulensis extract.